Novo Holdings leads $100 million Series C financing of Asceneuron to advance groundbreaking therapy for Alzheimer’s disease

Funds will be used to progress lead asset ASN51, an oral small molecule OGA inhibitor, into Phase 2 clinical development for the treatment of Alzheimer’s disease
Alzheimer’s disease is an area of very high unmet medical need with a lack of oral disease modifying therapies
Naveed Siddiqi, Senior Partner, Venture Investments, Novo Holdings will join Asceneuron Board of Directors

Copenhagen, Denmark, 16 July 2024 – Novo Holdings, a leading life science investor, today announces it led a $100 million Series C Financing in Asceneuron, a clinical stage biotech company developing small molecules targeting tau protein aggregation, a driver of neurodegenerative disease. The financing will be used to advance Asceneuron’s lead asset ASN51 into Phase 2 clinical development for the treatment of Alzheimer’s disease.

Locations